Testing antibody therapies

A small working group was convened to discuss some of the broad questions and issues arising from the Phase 1 TGN1412 trial in which participants experienced adverse events.

Launched

In March 2006, six volunteers taking part in a phase I clinical trial of a monoclonal antibody, TGN1412, experienced severe adverse events. As part of the Academy's on-going work into the research and development of new medicines, a small working group was convened to discuss some of the broad questions and issues arising from the TGN1412 trial. The project was completed within three months; an example of the Academy responding rapidly to an issue of national importance.   

East Anglia Regional Fellows event 2019

Book Now

Winter Science Meeting 2019

Book Now

Mentoring Masterclass - London

Book Now
View more
 
 
 
 
 
 
FB Twitter Instagram Youtube